Physician profile
Tamara Jane Baxter
NPI 1710331665
$3,166.73
in general payments reported to CMS, 2019-2025
18 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $627 · 2022: $968 · 2023: $1,189 · 2024: $224 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,035.46 | 2021-2024 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $595.06 | 2021-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.47 | 2021-2024 | Ofev |
| Amgen INC. | $283.03 | 2021-2023 | Tezspire |
| Insmed, INC. | $162.81 | 2021-2024 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $157.17 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.89 | 2022-2024 | Glassia |
| Genzyme Corporation | $120.24 | 2021-2023 | |
| Novo Nordisk INC | $72.83 | 2024-2025 | Ozempic, Rybelsus |
| Vapotherm INC | $52.10 | 2022 | |
| Philips North America LLC | $45.93 | 2022 | |
| Inogen, INC. | $38.27 | 2021-2023 | Inogen |
| Pulmonx Corporation | $34.23 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Exact Sciences Corporation | $33.00 | 2024-2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $26.91 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.95 | 2025 | Mounjaro, Zepbound |
| Actelion Pharmaceuticals US, INC. | $17.19 | 2022 | |
| Abbvie INC. | $15.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.